Skip to content
Vanity or Vice

Routines & Ingredients

Bemotrizinol Made It Through. Four Things It Still Does Not Fix.

The first new American sunscreen filter in a generation stopped being a proposal on June 10 and became a rule. That is genuinely good news, and it does not repair the filter drought, the shelf, the measurement, or the wavelengths that cause pigment.

Last updated

Vanity or Vice plate: what the order did, and did not — a new filter is available and at up to six percent in named forms are ticked; a proposed order is a product and the other filters move with it are crossed. An order is permission to formulate, not a bottle on a shelf. Verdict: on terms.

On June 10, 2026, bemotrizinol stopped being a proposal and became part of the American sunscreen monograph. First new ultraviolet filter added to the American monograph since the 1990s.

The path is worth knowing, because the coverage kept collapsing it. FDA issued a proposed order on December 12, 2025, took comments until January 26, 2026, and then published the final order — OTC000039, amending Monograph M020 — in June. Somewhere in that six-month gap, a large amount of writing announced a new approved sunscreen ingredient while it was still a document you could file an objection to. It is real now. It was not real then, and the difference matters if you were promised a product in January.

The terms, since almost nobody printed them: up to 6 percent as an active. Permitted in oil, lotion, cream, gel, butter, paste, ointment, stick and spray. And one condition on sprays that deserves its own sentence, because it quietly rules out a format Americans buy by the case.

Bemotrizinol is permitted at up to 6 percent in nine dosage forms — and the spray condition rules out the ordinary aerosol can.
Term of the order What it says
Order OTC000039, amending Over-the-Counter Monograph M020
Proposed order published December 12, 2025
Comment period closed January 26, 2026
Final order published June 10, 2026
Maximum concentration as an active 6 percent
Permitted dosage forms Oil, lotion, cream, gel, butter, paste, ointment, stick, spray
Condition on sprays No propellant at all, or a delivery system in which the propellant is fully isolated from the formulation
First US product on shelf August 31, 2026 — an airless jar, not a spray

The spray clause

A spray using bemotrizinol has to be manufactured and packaged with no propellant at all, or in a delivery system where the propellant is fully isolated from the formulation inside the container — no contact between the two, ever.

That is not the ordinary aerosol can. It is a pump, or a bag-on-valve arrangement where the product sits in a sealed pouch and the propellant pushes on the outside of it. Both exist. Both cost more than a standard aerosol, and the standard aerosol is what sits at eye level at every drugstore in the country every June. So if you were expecting the new filter to arrive first in the format you actually reach for, expect otherwise.

One: a filter is not the drought

The complaint about American sunscreen was never about one molecule. It is that the whole available filter set has barely moved in three decades while the rest of the world reformulated around better long-wave UVA protection, better photostability and better cosmetic behavior.

Bemotrizinol is a genuinely good addition to that set — broad, stable, widely used elsewhere for years. It is one addition. The gap between what an American formulator can reach for and what a Korean one can is narrower this month than last. It did not close.

Two: a monograph ingredient is not a bottle

GRASE status means a company can market a product containing bemotrizinol without filing a new drug application. It does not mean a single company has to reformulate anything. Somebody still has to build the formula, prove its SPF and broad-spectrum claims, source the raw material at volume, run stability, and decide the reformulation is worth the shelf fight.

One brand has now done it. Ultra Violette put Unblock Screen SPF 50 on sale at Sephora.com on August 31, 2026, eighty-two days after the final order, which it could only do because it had been selling bemotrizinol formulas elsewhere in the world for years and had a finished product waiting. A second, Fave Screen, is announced for January 2027. Note the format of the first one: an airless jar. Read the spray clause above and that stops being a coincidence.

One brand with a years-old overseas formula is not a category reformulating. Everybody else still has the whole queue to work through, and some of that queue is a business decision rather than a scientific one. Treat any other product claiming the new filter before the supply chain has plausibly caught up with the same suspicion you would give any other first-to-market claim.

Three: it does not change the ruler

Whatever gets formulated will be tested with the same method that produced 62.4 at one laboratory and 5.5 at another on the same bottle. A better filter measured by a soft instrument still arrives on the label as a soft number.

Which means the honest way to read a future bemotrizinol product is not by comparing its printed SPF to your current sunscreen’s printed SPF. That comparison sits inside the noise. The argument for the new filter is about what it absorbs and how stably it does it, not about a digit going up.

Four: it does not do anything about visible light

If your reason for wearing sunscreen is melasma, post-inflammatory hyperpigmentation, or any pigment that flares in summer, the wavelengths you most need blocked sit past the edge of where broad-spectrum testing stops looking. That is a job for iron oxides and tint, and the new filter does not touch it.

The same goes for the oldest problem in the category, which no regulator has ever legislated away: almost nobody applies enough.

Evidence check: Strong

Evidence level: the regulatory facts are drawn from the Federal Register final order and FDA’s own announcement, re-checked against the order on 19 September 2026 and unchanged since publication. The limitations described are structural rather than contested — they follow from what a monograph order does and does not do.

Sources reviewed September 19, 2026: FDA final order OTC000039, “Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use,” Federal Register, June 10, 2026. FDA, “FDA Expands Sunscreen Options for the First Time in 20 Years”. Proposed order published December 12, 2025; comment period closed January 26, 2026. First US launch date and format from trade coverage of Ultra Violette’s Unblock Screen SPF 50, on sale from August 31, 2026.

The Verdict

Worth being pleased about. Not worth waiting for.

Nothing about this order makes the sunscreen currently in your bathroom less protective than it was in May, and nothing about it justifies leaving that bottle unused while you wait for a better one to arrive. When a bemotrizinol product does land in front of you, judge it the way you would judge any other: on whether you will apply enough of it, on whether it covers the wavelengths your particular problem cares about, and on the amount rather than the number.

A new monograph filter after thirty years is a door opening. One brand with a formula already in hand has walked through it. That is not yet a category, and it is still not a delivery.

Checked against the June 10, 2026 Federal Register final order and FDA announcements; regulatory status and market availability re-verified 19 September 2026.